Dr. Ravi Ramjeesingh, MD, PhD, FRCPC
Assistant Professor Department of Community Health and Epidemiology
Staff Medical Oncologist, Nova Scotia Cancer Center
Member of the Breast, Gastrointestinal and Melanoma Cancer Disease Site Working Groups
Dalhousie University, Capital Health
Clinical expertise is in the areas of Gastrointestinal cancers primarily pancreatic and hepatobiliary tumors, Breast Cancer and Melanoma. He is the medical oncology lead in hepatopancreobiliary tumors, being the principle investigator in several industry and academic clinical trials. His research activities and interests are in the fields of Health service delivery, Clinical and Research Databases, and translational research in Oncology. Administrative and academic responsibilities have included membership of the CCTG Canadian Gastrointestinal Disease Oncology Group, Medical advisor for Craig’s Cause Pancreatic Cancer Society, faculty member of oncologyeducation.com, faculty member for the Novartis Oncology Young Canadian Investigator Award (NOYCIA) and Associate Member of the Beatrice Hunter Cancer Research Institute (BHCRI).
Currently Dr. Ramjeesingh is heading an initiative to create a provincial pancreatic cancer database and associated tumor bank. As the lead investigator of The PANcreatic Cancer Research platform to Examine biomarkers And Systemic treatment outcomes (PANCREAS) project, working with other investigators he hopes to begin to tackle questions about referral patterns, and patient outcomes in the province and begin to investigate biomarkers for pancreatic cancer. As a medical oncologist, Dr. Ramjeesingh is interested in clinical trials with an emphasis on phase II and III clinical trials for gastrointestinal and breast cancers.
Membership Status:Dr. Ramjeesingh is a BHCRI Associate Member
Phone:902 473 6106
Address:Bethune Building, QEII Health Sciences Centre, 1276 South Park Street, Halifax, Nova Scotia, Canada B3H 2Y9
Graham C, Orr C, Bricks CS, Hopman WM, Hammad N, Ramjeesingh R. A retrospective analysis of the role of proton pump inhibitors on colorectal cancer disease survival. Curr Oncol 2016 Dec;23(6):e583-e588.
Wang A, Ramjeesingh R, Chen CH, Hurlbut D, Hammad N, Mulligan LM, Nicol C, Feilotter HE, Davey S. Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma. Curr Oncol 2016 June;23(3):e171-e178.
Ramjeesingh R, Orr C, Bricks CS, Hopman WM, Hammad N. A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival. Curr Oncol 2016 Apr;23(2):e116-122.
Ramjeesingh R, Meyer RM, Brouwers M, Booth CM. Alignment of practice guidelines with targeted therapy drug funding policies in Ontario. Curr Oncol 2013 Feb;20(1):e21-33.